Bausch Health Companies Inc BHC Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Paulson John

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,890

Price:

$10.61
Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Icahn Brett

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

3,122

Price:

$10.61
Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Robertson Russel C

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

2,945

Price:

$10.61
Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Wechsler Amy B

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

647

Price:

$10.61
Mar 04, 2024 (filed on Mar 04, 2024)

Insider Name:

Carson Seana

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-133

Price:

$9.80
Mar 04, 2024 (filed on Mar 04, 2024)

Insider Name:

Carson Seana

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,561

Price:

$9.80
Mar 04, 2024 (filed on Mar 04, 2024)

Insider Name:

Carson Seana

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-199

Price:

$9.80
Mar 04, 2024 (filed on Mar 04, 2024)

Insider Name:

Carson Seana

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,420

Price:

$9.80
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Barresi John S

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-3,188

Price:

$9.89
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Appio Thomas

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-87,803

Price:

$9.89

Filings by filing date

Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Paulson John

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,890

Price:

$10.61
Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Icahn Brett

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

3,122

Price:

$10.61
Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Robertson Russel C

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

2,945

Price:

$10.61
Mar 29, 2024 (filed on Apr 01, 2024)

Insider Name:

Wechsler Amy B

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

647

Price:

$10.61
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Barresi John S

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-3,188

Price:

$9.89
Feb 29, 2024 (filed on Mar 04, 2024)

Insider Name:

Barresi John S

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,126

Price:

--
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Appio Thomas

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-87,803

Price:

$9.89
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Appio Thomas

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-23,871

Price:

$9.89
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Appio Thomas

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,413

Price:

$9.89
Mar 01, 2024 (filed on Mar 04, 2024)

Insider Name:

Appio Thomas

Ownership Type:

Direct Ownership

Securities:

Common Shares, No Par Value

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,895

Price:

$9.89

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	2150 Saint-Elzear Blvd W LAVAL QC H7L 4A8
Tel:	N/A
Website:	https://www.bauschhealth.com
IR:	See website

Key People

Thomas J. Appio Chief Executive Officer, Director	John S. Barresi Interim Chief Financial Officer	Seana-Lyn Carson Executive Vice President, General Counsel

Business Overview

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Financial Overview

For the fiscal year ended 31 December 2023, Bausch Health Companies Inc revenues increased 8% to $8.76B. Net loss increased from $225M to $592M. Revenues reflect Bausch & Lomb / International segment increase of 10% to $4.15B, Salix segment increase of 8% to $2.25B, International Rx segment increase of 8% to $1.07B, United States and Puerto Rico segment increase of 7% to $5.19B, Other Foreign Countries segment increase of 14% to $1.01B.

Employees:	20,270 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$24,607M as of Dec 31, 2023
Annual revenue (TTM):	$8,757M as of Dec 31, 2023
EBITDA (TTM):	$2,863M as of Dec 31, 2023
Net annual income (TTM):	-$592.00M as of Dec 31, 2023
Free cash flow (TTM):	$760.00M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$21,441M as of Dec 31, 2023
Shares outstanding:	366,672,723 as of Mar 15, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization